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Abstract 
CASP8AP2 was initially identified as a pro-
apoptotic protein that transmits an apoptosis 
indication through the death-inducing signaling 
complex.  
More recently, diverse functions have been 
described including TNF-induced NF-kappaB 
activation, cell-cycle progression and cell division, 
regulation of histone gene transcription and histone 
mRNA processing. 
Keywords 
CASP8AP2 
Identity 
Other names: FLASH, CED-4, FLJ11208, 
KIAA1315, RIP25 
HGNC (Hugo): CASP8AP2 
Location 
6q15 ; CASP8AP2 gene is located on the long arm 
of chromosome 6 NC_000006.12, in opposite 
orientation 
DNA/RNA 
Description 
44,537 bp; 10 exons 
Transcription 
Three transcripts reported at NCBI: Variant1, 
6,821bp NM_012115.3; Variant2, 6,782bp 
NM_001137667.1; Variant3, 6,649bp 
NM_001137668.1. Alternative splicing results in 
multiple transcript variants encoding the same 
protein. 
Protein 
Description 
Size 1982 amino acids; 222,658 kDa protein.  
It contains a motif structurally related to 
CED4/Apaf1 (602233) and a C-terminal death 
effector domain (DED)-recruiting domain (DRD); a 
NCOA2-binding domain (position 1709-1982aa); a 
SUMO interaction motifs: SIM1 (position 1683-
1687aa), SIM2 (position 1737-1741aa, SIM3 
(position 1794-1798aa) which mediate the binding to 
polysumoylated substrates.  
The FLASH activity is regulated by sumoylation 
(Alm-Kristiansen et al., 2009). 
Localisation 
Nucleus, cytoplasm, mitochondrion. 
Function 
Component of the apoptosis signaling pathway 
required for the activation of CASP8 in Fas-
mediated apoptosis (Imai Y et al., 1999).  
Component of the machinery required for histone 
precursor mRNA expression and essential for 3end 
maturation of histone mRNAs (Barcaroli D et al., 
2006; De Cola et al., 2012; Yang XC et al., 2009).  
It participates in TNF-alpha-induced blockade of 
glucocorticoid receptor transactivation at the nuclear 
receptor coactivator level, upstream and 
independently of NF-kappa-B (Kino and Chrousos, 
2003). It also contributes to cell cycle progression at 
S phase (Kiriyama et al., 2009; Barcaroli D et al., 
2006). 
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Genomic location and gene products of CASP8AP2. The gene is located at 6q15, it has three transcripts, and all of them encode 
the same protein. 
 
Homology 
Caenorhabditis elegans protein CED-4; Mus 
musculus protein FLASH 
Implicated in 
t(6;11)(q15;q23) 
Disease 
Acute myeloid leukemia. A t(6;11)(q15;q23) in a 50-
year-old Korean woman with acute myeloid 
leukemia has been reported (Park TS et al., 2009). 
Hybrid/Mutated gene 
A MLL/CASP8AP2 fusion was identified by LDI-
PCR and sequencing, a rearrangement between MLL 
(intron 8) and CASP8AP2 (intron 7) was detected at 
the genomic DNA level. The breakpoint analysis at 
the transcription level was not performed due to lack 
of a cDNA specimen 
Oncogenesis 
MLL/CASP8AP2 seems to be related to poor 
clinical outcome, however, further studies are 
needed to evaluate prognosis. 
Acute lymphoblastic leukemia 
CASP8AP2 low expression 
Prognosis 
The clinical significance of CASP8AP2 was first 
reported by (Flotho C et al., 2006), the differences in 
its expression levels were significantly associated 
with early response to treatment and the presence of 
minimal residual disease (MRD). CASP8AP2 
expression was analyzed in 99 children with acute 
lymphoblastic leukemia (ALL) enrolled in the St. 
Jude Total Therapy Study XIII protocol. Patients 
with low levels of expression presented a lower 
event-free survival and higher incidence of relapse, 
in contrast to patients with higher expression levels. 
High expression was associated with greater 
propensity of leukemic cells to undergo apoptosis. In 
this study CASP8AP2 was considered as an 
independent prognostic marker for relapse (Flotho C 
et al., 2006).  
The usefulness of CASP8AP2 expression as a 
potential marker of response to treatment has been 
analyzed in leukemic patients from different 
populations. In a cohort of 39 newly diagnosed ALL 
children treated with the Beijing Children`s Hospital 
(BCH)-ALL 2003 protocol, the bone marrow 
expression of CASP8AP2 at diagnosis resulted a 
suitable indicator of relapse. In the same study, 
another cohort of 106 patients enrolled in the 
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Chinese Childrens Leukemia Group (CCLG)-ALL 
2008 protocol were also analyzed, patients with low 
CASP8AP2 expression showed higher relapse rates, 
lower relapse-free survival and lower overall-
survival, in comparison to the higher-expression 
group (Jiao Y et al., 2012). ).  
In an independent study a gene signature of 14 genes, 
including CASP8AP2 and H2AFZ, was identified 
(Flotho C et al., 2007); their low expressions were 
associated to relapse. Based on this result, the 
expressions of CASP8AP2 and H2AFZ were 
analyzed in a cohort of 88 ALL Mexican children 
treated with the Popular Medical Insurance protocols 
(Juárez-Velázquez R et al., 2014). An increased risk 
for early relapse in patients with low expression of 
CASP8AP2 was found, confirming its usefulness as 
a risk marker; the H2AFZ expression did not showed 
the same effect. The CASP8AP2 expression was not 
an independent marker of relapse, but combined 
characteristics as the low expressions of both genes 
and high white blood cell count, identified more 
accurately patients at greater risk of relapse (Juárez-
Velázquez R et al., 2014). Although the prognostic 
value of CASP8AP2 expression as an independent 
factor is controversial (Yang YL et al., 2010), 
combined with expressions of other genes such as 
H2AFZ (Juárez-Velázquez R et al., 2014) and ARS2 
(Cui L et al., 2015), could more precisely predict 
high risk of relapse in ALL. ).  
Epigenetic modifications are also related to the 
down-regulation of CASP8AP2. DNA 
hypermethylation of the gene promoter was analyzed 
in 86 children with ALL, treated according to the 
BCH-2003 and CCLG-2008 protocols. The 
percentage of methylation of two CpG sites at 
positions -1189 and -1176 were inversely correlated 
with mRNA expression. The patients with higher 
methylation presented MRD and poor treatment 
outcome. The results suggested that combination of 
methylation level and MRD might improve current 
risk stratification (Li ZG et al., 2013). In regard to 
these findings, it has been demonstrated that 
methylation of the CASP8AP2 promoter in somatic 
stem cells and cancer cells increase their resistance 
to drugs (Lee KD et al., 2012). These data associate 
this epigenetic modification with the development of 
drug resistance. 
T-cell acute lymphoblastic leukemia)   
(T-ALL) 
A del(6)(q15-q16.1)  has been reported in 
approximately 12% of T-ALL  patients. This 
deletion includes the CASP8AP2 gene, whose 
mRNA expression was the single most down-
regulated gene of all 7 genes located in the deleted 
region. 
Prognosis 
The lower expression of CASP8AP2 has been also 
associated to deletions at band 6q15-q16.1, which 
are often detected in patients with T-ALL (Remke M 
et al., 2009). These deletions result in down 
regulation of the gene and poor early response to 
treatment. In 73 T-cell ALL samples obtained from 
patients enrolled in the multicenter ALL-BFM 1990, 
ALL-BFM 1995 and ALL-BFM 2000 protocols, 
deletion 6q15-q16.1 was associated with 
unfavorable MRD levels. Although deletion 6q15-
q16.1 involves several genes, CASP8AP2 was the 
single one with a better association between the 
deletion and the less efficient induction of apoptosis 
by chemotherapy (Remke M et al., 2009). 
Cytogenetics 
The del(6)(q15-q16.1)comprises 2.54 Mb. 
Diffuse large B-cell lymphomas )( 
activated B-cell like subtype) 
Loss of CASP8AP2 in 35% of cases. Imbalance with 
possible pathogenic relevance (Scholtysik R et al., 
2015). 
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